Infections caused by fluoroquinolone-resistant Escherichia coli following transrectal ultrasound-guided biopsy of the prostate

Suwantarat, Nuntra; Rudin, Susan D.; Marshall, Steven H.; Hujer, Andrea M.; Pérez, Federico; Hujer, Kristine M.; Domitrovic, Tatiana; Dumford, Donald M.; Donskey, Curtis J.

doi:10.1016/j.jgar.2013.07.003

Cited by 12 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this research, we observed two clones with 94.1% similarity and one clone with less than 85% similarity ( Figure 1 ). Our analysis of multi-locus sequence typing confirmed the presence of the pandemic B2-ST131 E. coli clone by the Achtman scheme in all ST43 isolates obtained by the Institute Pasteur scheme, in agreement with previous studies [ 5 ]. As such, it is important to maintain a surveillance system for the identification of clones representing a public health threat, particularly those that occur outside of the hospital environment.…”

supporting

confidence: 92%

First Detection of the CTXM-15 Producing Escherichia coli O25-ST131 Pandemic Clone in Ecuador

2018

View full text Add to dashboard Cite

Our aim was identify of the pandemic B2-ST131 Escherichia coli clone by to the Institute Pasteur and Achtman scheme, and investigate the resistance profile phenotypic-genotypic, with identification of class 1 integron. Of thirty-five ESBL-producing isolates recovered of patients with diagnosis of urinary tract infections (UTI), six E. coli strains serotype O25 were identified with resistance antimicrobial to several groups of antibiotics such as broad-spectrum cephalosporins, fluoroquinolones and aminoglycosides, harboring blaSHV, blaCTX-M genes in all isolates and blaTEM in two isolates. Sequencing of blaCTX-M revealed CTX-M-15 in all strains. The PMQR aac(6´)-Ib-cr and qnrB19 genes were presented in five and four isolates respectively, AMEs genes aac(6´)-Ib and aac(3)-IIa were presented in strain amikacin-gentamicin-resistant. Sequencing of the variable regions of the class 1 integron revealed dfrA and aadA genes cassette. The analysis of multilocus sequence typing (MLST) confirms the presence of the pandemic B2-ST131 E. coli clone by Achtman scheme in all ST43 isolates obtained by of the Institute Pasteur scheme. The results presented herein, reveal the presence of B2-ST131 E. coli clone in Ecuador, disseminated in hospitals and community settings.

show abstract

supporting

confidence: 92%

First Detection of the CTXM-15 Producing Escherichia coli O25-ST131 Pandemic Clone in Ecuador

2018

View full text Add to dashboard Cite

show abstract

“…Along with multiple case reports, previous cross‐sectional studies have shown that 8–11% of patients presenting with PA had recently undergone prostate biopsies . In two such cases, PA was the result of infection with multidrug‐resistant Escherichia coli . As patients undergoing transrectal prostate biopsy are frequently given antimicrobial prophylaxis, it is important to be mindful of the rising emergence of multidrug resistance in post‐prostate biopsy infections …”

Section: Etiology and Natural Historymentioning

confidence: 99%

“…These patients, who are frequently older with coincident outlet obstruction, are at risk for PA from direct introduction of bacteria into the prostate. Along with multiple case reports, [21][22][23][24] previous cross-sectional studies have shown that 8-11% of patients presenting with PA had recently undergone prostate biopsies. 25,26 In two such cases, PA was the result of infection with multidrug-resistant Escherichia coli.…”

Section: Etiology and Natural Historymentioning

confidence: 99%

“…25,26 In two such cases, PA was the result of infection with multidrug-resistant Escherichia coli. 21,23 As patients undergoing transrectal prostate biopsy are frequently given antimicrobial prophylaxis, it is important to be mindful of the rising emergence of multidrug resistance in post-prostate biopsy infections. 27 Novel gland-conserving therapies directed at prostate cancer, such as cryotherapy 28 and brachytherapy, 29 are also associated with rare complications of PA; several reports also detail PA after intravesical BCG for bladder cancer.…”

Section: Etiology and Natural Historymentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis and treatment of patients with prostatic abscess in the post‐antibiotic era

2017

View full text Add to dashboard Cite

We reviewed the pathogenesis, clinical presentation, treatment options and outcomes of prostatic abscess in the post-antibiotic era, focusing on how patient risk factors and the emergence of multidrug-resistant organisms influence management of the condition. A MEDLINE search for "prostate abscess" or "prostatic abscess" was carried out. Prostate abscess is no longer considered a consequence of untreated urinary infection; now, men with prostatic abscess are typically debilitated or immunologically compromised, with >50% of patients having diabetes. In younger men, prostatic abscess can be the initial presentation of such chronic conditions. In older men, prostatic abscess is increasingly a complication of benign prostatic hyperplasia or prostate biopsy. Diagnosis is based on a physical examination, leukocytosis, leukocyturia and transrectal ultrasound, with magnetic resonance imaging serving as the preferred confirmatory imaging modality. Treatment of prostatic abscess is changing as a result of the emergence of atypical and drug-resistant organisms, such as extended-spectrum blactamase-producing enterobacteriaceae and methicillin-resistant Staphylococcus aureus. As many as 75% of infections are resistant to first-generation antibiotics, necessitating aggressive therapy with broad-spectrum parenteral antibiotics, such as third-generation cephalosporins, aztreonam or antibiotic combinations. A total of 80% of patients require early surgical drainage, frequently through a transurethral approach. In the postantibiotic era, prostatic abscess is evolving from an uncommon complication of urinary infection to a consequence of immunodeficiency, growing antibiotic resistance and urological manipulation. This condition, primarily affecting patients with chronic medical conditions rendering them susceptible to atypical, drug-resistant organisms, requires prompt aggressive intervention with contemporary antibiotic therapy and surgical drainage.

show abstract

“…The 2016 FDA communication recommended that fluoroquinolones should not be used for patients with acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated urinary tract infections unless no alternative treatment options were available [10]. We have previously reported increasing rates of fluoroquinolone resistance among Escherichia coli urinary tract isolates from our facility [11–13]. Urologists and primary care providers were alerted to the problem of increasing fluoroquinolone resistance in 2010 due to an outbreak of infections with fluoroquinolone-resistant E. coli after transrectal ultrasound-guided prostate biopsy [11–12].…”

Section: Discussionmentioning

confidence: 99%

Impact of Reduced Fluoroquinolone Use on Clostridioides difficile Infections Resulting From the Fluoroquinolone-Resistant Ribotype 027 Strain in a Veterans Affairs Medical Center

Redmond

Silva

Wilson

et al. 2019

PAI

Self Cite

View full text Add to dashboard Cite

Background: Fluoroquinolone restriction has been proposed as a control measure for Clostridioides difficile infection (CDI) outbreaks associated with fluoroquinolone-resistant ribotype 027 strains. However, relatively few reports of fluoroquinolone restriction interventions have evaluated the impact on C. difficile strain types and fluoroquinolone resistance.Methods: In a hospital and affiliated long-term care facility (LTCF), antimicrobial stewardship and environmental cleaning interventions were implemented between 2009 and 2018, and C. difficile isolates during this period (~20 per year) were ribotyped and tested for fluoroquinolone resistance by moxifloxacin minimum inhibitory concentrations (MICs). Pearson’s correlation coefficient was used to assess the association between use of fluoroquinolones and the percentage of CDI cases due to the 027 strain over time.Results: Between 2009 and 2018, prescribing of fluoroquinolones to inpatients decreased by 43%, coinciding with significant reductions in the healthcare-associated CDI rates in the hospital and LTCF and a decline in the percentage of C. difficile isolates that were ribotype 027 from 70% to 10%. Ninety-five percent of ribotype 027 and 6% of non-027 isolates were moxifloxacin resistant. Hospital fluoroquinolone use was strongly correlated with the incidence of hospital-associated CDI (r = 0.79, 95% confidence interval, 0.31-0.95), but LTCF fluoroquinolone use was not correlated with LTCF-associated CDI (r = 0.29, 95% confidence interval, -0.43-0.77). During the study period, there were statistically significant downward trends in the use of penicillins, intravenous vancomycin, carbapenems, and clindamycin.Conclusion: Our results provide support for fluoroquinolone restriction as a control measure for CDI outbreaks due to fluoroquinolone-resistant 027 strains, but also highlight the need for randomized trials as factors such as reduction in other antibiotic classes and improved cleaning may also impact CDI rates.

show abstract

Infections caused by fluoroquinolone-resistant Escherichia coli following transrectal ultrasound-guided biopsy of the prostate

Cited by 12 publications

References 21 publications

First Detection of the CTXM-15 Producing Escherichia coli O25-ST131 Pandemic Clone in Ecuador

First Detection of the CTXM-15 Producing Escherichia coli O25-ST131 Pandemic Clone in Ecuador

Diagnosis and treatment of patients with prostatic abscess in the post‐antibiotic era

Impact of Reduced Fluoroquinolone Use on Clostridioides difficile Infections Resulting From the Fluoroquinolone-Resistant Ribotype 027 Strain in a Veterans Affairs Medical Center

Contact Info

Product

Resources

About